ClinicalTrials.gg

Program

crinecerfont

Also written as “Crinecerfont”, “NBI-74788” and “SSR125543”.

Its studies are mostly in Adrenal Hyperplasia, Congenital · Depressive Disorder, Major, led by 2 companies.

Furthest: phase 3, since Jul 24, 20207 company-led studies, 4 open or runningNext primary completion: Mar 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Neurocrine Biosciences64 open or runningphase 3since Jul 24, 2020May 2, 2018Mar 2028phase 2 · NCT07536269
Sanofi10 open or runningphase 2since Dec 17, 2009Dec 17, 2009none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 17, 2009First study: phase 2 study in Depressive Disorder, MajorNew to SanofiSanofi · NCT01034995 · 580 enrolled · Belgium, Canada, Chile and more
  2. May 2, 2018Neurocrine Biosciences's first study: phase 2 study in Adrenal Hyperplasia, CongenitalNew to Neurocrine BiosciencesNeurocrine Biosciences · NCT03525886 · 18 enrolled · United States
  3. Jul 31, 2019Phase 2 study in Adrenal Hyperplasia, CongenitalNeurocrine Biosciences · NCT04045145 · 8 enrolled · United States
  4. Jul 24, 2020Phase 3 study in Adrenal Hyperplasia, CongenitalNeurocrine Biosciences · NCT04490915 · 182 enrolled · United States, Austria, Belgium and more
  5. Mar 16, 2021Phase 3 study in Adrenal Hyperplasia, CongenitalNeurocrine Biosciences · NCT04806451 · 103 enrolled · United States, Belgium, Canada and more
  6. Sep 18, 2025Phase 2 study in Adrenal Hyperplasia, CongenitalNeurocrine Biosciences · NCT07187375 · 7 enrolled · Germany
  7. Apr 10, 2026Phase 2 study in Adrenal Hyperplasia, CongenitalNeurocrine Biosciences · NCT07536269 · 20 planned · United States

Ahead

  1. Mar 2028Primary completion: phase 2 study in Adrenal Hyperplasia, CongenitalNeurocrine Biosciences · NCT07536269
  2. Sep 6, 2029Primary completion: phase 2 study in Adrenal Hyperplasia, CongenitalNeurocrine Biosciences · NCT07187375

TargetBeta

CRHR1 →read by rule
“Corticotropin releasing factor receptor 1 antagonist”ChEMBL 37, by rule

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07536269Adrenal Hyperplasia, Congenital · United States2RecruitingNeurocrine BiosciencesMar 202820
NCT07187375Adrenal Hyperplasia, Congenital · Germany2Active, not recruitingNeurocrine BiosciencesSep 6, 20297
NCT04806451Adrenal Hyperplasia, Congenital · United States, Belgium, Canada and more3Active, not recruitingNeurocrine BiosciencesMar 10, 2023103
NCT04490915Adrenal Hyperplasia, Congenital · United States, Austria, Belgium and more3Active, not recruitingNeurocrine BiosciencesJul 19, 2023182
NCT04045145Adrenal Hyperplasia, Congenital · United States2CompletedNeurocrine BiosciencesJul 2, 20218
NCT03525886Adrenal Hyperplasia, Congenital · United States2CompletedNeurocrine BiosciencesApr 7, 202018
NCT01034995Depressive Disorder, Major · Belgium, Canada, Chile and more2CompletedSanofiMar 2011580

How it is read

Names in the registry

  • “Crinecerfont”, 5 entries
  • “NBI-74788”, 1 entry
  • “SSR125543”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.